📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. (2018)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/eurheartj/ehy249

PubMed Identifier: 29741611

Publication URI: http://europepmc.org/abstract/MED/29741611

Type: Journal Article/Review

Volume: 39

Parent Publication: European heart journal

Issue: 43

ISSN: 0195-668X